OKLAHOMA CITY, Oklahoma, September 27, 2023 – Cytovance Biologics, a leading full-service mammalian and microbial large molecule contract development and manufacturing organization (CDMO), announced today the addition of Axel Schleyer, Ph.D., MBA, as Chief Commercial Officer (CCO). Dr. Schleyer brings over 20 years of international clinical and commercial CDMO experience to the company, with particular […]

OKLAHOMA CITY, January 16, 2023 — Cytovance Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian and microbial biologics, announces the appointment of Mr. Ping Zhang as Chief Executive Officer.

Oklahoma City, Oklahoma – July 13, 2020 – Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the promotion of Dr. John Mott to Vice President of Development. Dr. Mott will serve on the Senior Leadership Team and report to Dr. Jesse McCool, Chief Executive Officer for Cytovance Biologics. “I am very excited

Oklahoma City, Oklahoma – July 6, 2020 – Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces Yuk Chun Chiu as Vice President of Manufacturing Operations. Mr. Chiu will serve on the Senior Leadership Team and report to Dr. Jesse McCool, Chief Executive Officer for Cytovance Biologics. “I am thrilled to be welcoming

Oklahoma City, Oklahoma, April 30, 2020 – Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the appointment of Matthew Delaney to Vice President of Business Development and Marketing. Mr. Delaney will serve on the Senior Leadership Team and report to Dr. Jesse McCool, Chief Executive Officer for Cytovance Biologics. “We are delighted

Oklahoma City, Oklahoma, March 30, 2020 – Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the appointment of Dr. Jesse McCool to Chief Executive Officer. Dr. Yan Wang will step down as Cytovance’s interim CEO while continuing to serve as Director of the Board for Cytovance and CEO of SPL (Waunakee, WI).

Oklahoma City, OK – June 27, 2019 –  Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announced today the appointment of Jesse McCool, Ph.D. as Chief Technology Officer.  Dr. McCool will continue to provide scientific and operational oversight as the SVP of R&D Services and will be responsible for leading Cytovance’s overall technology

Oklahoma City, OK. – May 10th, 2019 – Cytovance® Biologics, Inc., a leading full-service biopharmaceutical contract manufacturer of mammalian and microbial biologics, has promoted Matt Hamilton to Vice President, Finance. Mr. Hamilton will be leading the Finance and Accounting function. Matt has been acting Vice President of Finance for the past ten months and was

OKLAHOMA CITY, Jan. 15, 2018 (GLOBE NEWSWIRE) –– Cytovance® Biologics, Inc., a leading full-service biopharmaceutical contract manufacturer of mammalian and microbial biologics, announces and welcomes Edwin Miranda as Vice President of Quality.  Edwin Miranda will be leading the full breadth of Cytovance’s Quality function. “With over 33 years’ experience in the biopharmaceutical contract manufacturing industry,

Oklahoma City, OK – March 14, 2017- Cytovance® Biologics, a leading CDMO who provides unparalleled support to biopharmaceutical companies to move candidate molecules from the bench to commercial manufacturing, announces today that it has received a CMO Leadership Award in three categories; Quality, Reliability and Compatibly, which will be given at the CMO Leadership Awards